More broadly, Schneider et al. emphasized the importance of tissue-specific tumorigenesis: although multiple cancers may share similar driver mutations (e.g., KRAS, TP53), the phenotypic consequences differ among tissues due to variations in microenvironment, cell of origin, and signaling context. This evidence concerns the gene KRAS and cancer.